Can microorganisms develop resistance against light based anti-infective agents?

Marasini, Sanjay; Leanse, Leon G.; Dai, Tianhong

doi:10.1016/j.addr.2021.05.032

Cited by 43 publications

(39 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The discrepancies in the results that were obtained by various research groups raise the question of the need for standardized protocols for the testing of bacterial resistance to light-based therapies, which was also highlighted in the latest review by Marasini et al (2021). The authors suggested that in future research, it is important to assess reproducibility during assessment of the potential development of tolerance or resistance, and we agree with this statement [ 57 ]. The literature shows that Gram-negative bacteria, including E. coli , have repeatedly acquired adaptations to many chemical factors, such as acids [ 58 , 59 ], organic solvents [ 33 , 34 ], heavy metals [ 60 , 61 ], and physical factors such as ionizing [ 37 ] or UV radiation [ 35 ].…”

Section: Discussionmentioning

confidence: 55%

Can Gram-Negative Bacteria Develop Resistance to Antimicrobial Blue Light Treatment?

Rapacka-Zdończyk

Woźniak

Kruszewska

et al. 2021

IJMS

View full text Add to dashboard Cite

Antimicrobial blue light (aBL) treatment is considered low risk for the development of bacterial resistance and tolerance due to its multitarget mode of action. The aim of the current study was to demonstrate whether tolerance development occurs in Gram-negative bacteria. We evaluated the potential of tolerance/resistance development in Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa and demonstrated that representative Gram-negative bacteria may develop tolerance to aBL. The observed adaption was a stable feature. Assays involving E. coli K-12 tolC-, tolA-, umuD-, and recA-deficient mutants revealed some possible mechanisms for aBL tolerance development.

show abstract

Section: Discussionmentioning

confidence: 55%

Can Gram-Negative Bacteria Develop Resistance to Antimicrobial Blue Light Treatment?

Rapacka-Zdończyk

Woźniak

Kruszewska

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Given the multi-targeted nature of aPDT, the possibility for microorganisms to develop resistance is supposed to be very limited [36]. However, they may be able to respond to aPDT in different ways.…”

Section: Biological Effects Of Apdt: Potential Targets and Related Me...mentioning

confidence: 99%

Antimicrobial Photodynamic Therapy: Latest Developments with a Focus on Combinatory Strategies

et al. 2021

View full text Add to dashboard Cite

Antimicrobial photodynamic therapy (aPDT) has become a fundamental tool in modern therapeutics, notably due to the expanding versatility of photosensitizers (PSs) and the numerous possibilities to combine aPDT with other antimicrobial treatments to combat localized infections. After revisiting the basic principles of aPDT, this review first highlights the current state of the art of curative or preventive aPDT applications with relevant clinical trials. In addition, the most recent developments in photochemistry and photophysics as well as advanced carrier systems in the context of aPDT are provided, with a focus on the latest generations of efficient and versatile PSs and the progress towards hybrid-multicomponent systems. In particular, deeper insight into combinatory aPDT approaches is afforded, involving non-radiative or other light-based modalities. Selected aPDT perspectives are outlined, pointing out new strategies to target and treat microorganisms. Finally, the review works out the evolution of the conceptually simple PDT methodology towards a much more sophisticated, integrated, and innovative technology as an important element of potent antimicrobial strategies.

show abstract

“…[42] Last but not least, the afterglow emission is used as an internal light source to persistently excite photosensitizers and generate ROS, which could overcome the short half-life and durability of traditional PDT. [15] ZGC NDs could be activated by LED (300-600 nm), making mPL@Pc-Cy NPs no longer limited by the afterglow time. The persistent and repeatable PDT avoids excessively high ROS levels in a short time period, which could alleviate oxidative stress and minimize side effects.…”

Section: In Vivo Treatment Safety Of Mpl@pc-cy/lightmentioning

confidence: 99%

“…[ 14 ] Light‐based antibacterial approaches possess the potential to kill a wide range of bacteria with high spatial and temporal precision, irrespective of bacterial drug resistance status. [ 15 ] Photothermal therapy (PTT) offers thermal inactivation of bacteria; however, the elevated temperature (over 50 °C) may damage the surrounding healthy tissues and even produce heat shock proteins to generate resistance to PTT. [ 16 ] Photodynamic therapy (PDT) generates reactive oxygen species (ROS) to destruct bacterial membrane, protein, and DNA for non‐specific sterilization while causing negligible drug resistance.…”

Section: Introductionmentioning

confidence: 99%

Persistent Luminescence‐Based Theranostics for Real‐Time Monitoring and Simultaneously Launching Photodynamic Therapy of Bacterial Infections

Zhang

Yan

Qiu

et al. 2022

Small

View full text Add to dashboard Cite

External light irradiation is usually required in bacterial infection theranostics; however, it is always accompanied by limited light penetration, imaging interference, and incomplete bacterial destruction. Herein, a feasible “image‐launching therapy” strategy is developed to integrate real‐time optical imaging and simultaneous photodynamic therapy (PDT) of bacterial infections into persistent luminescence (PL) nanoparticles (NPs). Mesoporous silica NPs are used as a substrate for in situ deposition of PL nanodots of ZnGa2O4:Cr3+ to obtain mPL NPs, followed by surface grafting with silicon phthalocyanine (Si‐Pc) and electrostatic assembly of cyanine 7 (Cy7) to fabricate mPL@Pc‐Cy NPs. The PL emission of light‐activated mPL@Pc‐Cy NPs is quenched by Cy7 assembly at physiological conditions through the fluorescence resonance energy transfer effect, but is rapidly restored after disassembly of Cy7 in response to bacterial infections. The self‐illuminating capabilities of NPs avoid tissue autofluorescence under external light irradiation and achieve real‐time colorimetric imaging of bacterial infections. In addition, the afterglow of mPL NPs can persistently excite Si‐Pc photosensitizers to promote PDT efficacy for bacterial elimination and accelerate wound full recovery with normal histologic features. Thus, this study expands the theranostic strategy for precise imaging and simultaneous non‐antibiotic treatment of bacterial infections without causing side effects to normal tissues.

show abstract

Can microorganisms develop resistance against light based anti-infective agents?

Cited by 43 publications

References 86 publications

Can Gram-Negative Bacteria Develop Resistance to Antimicrobial Blue Light Treatment?

Can Gram-Negative Bacteria Develop Resistance to Antimicrobial Blue Light Treatment?

Antimicrobial Photodynamic Therapy: Latest Developments with a Focus on Combinatory Strategies

Persistent Luminescence‐Based Theranostics for Real‐Time Monitoring and Simultaneously Launching Photodynamic Therapy of Bacterial Infections

Contact Info

Product

Resources

About